Λετονία -
Λετονικά -
Zāļu valsts aģentūra
propofol-lipuro 2% (20 mg/ml), emulsija injekcijām vai infūzijām
b.braun melsungen ag, germany - propofols - emulsija injekcijām/infūzijām - 20 mg/ml
Λετονία -
Λετονικά -
Zāļu valsts aģentūra
anesia 20 mg/ml emulsija injekcijām/infūzijām
baxter holding b.v., netherlands - propofols - emulsija injekcijām/infūzijām - 20 mg/ml
Λετονία -
Λετονικά -
Zāļu valsts aģentūra
kabiven emulsija infūzijām
fresenius kabi ab, sweden - kalcija chloridum, magnija sulfas, glikozi, soiae naftas raffinatum, alaninum, argininum, methioninum, leucinum, skābes asparticum, skābes glutamicum, glycinum, histidinum, isoleucinum, lysinum, phenylalaninum, prolinum, serinum, threoninum, tryptophanum, tyrosinum, valinum, natrii glycerophosphas, kalii chloridum, natrii acetas - emulsija infūzijām
Λετονία -
Λετονικά -
Zāļu valsts aģentūra
ringer fresenius šķīdums infūzijām
fresenius kabi polska sp.z o.o., poland - kalcija chloridum, kalii chloridum, natrii chloridum - Šķīdums infūzijām
Ευρωπαϊκή Ένωση -
Λετονικά -
EMA (European Medicines Agency)
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - prostatas audzējiem, kastrācija-izturīgs - terapeitiskie radiofarmaceitiskie preparāti - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.